Stock Analysis
Fluicell (STO:FLUI) Third Quarter 2023 Results
Key Financial Results
- Revenue: kr589.0k (up 15% from 3Q 2022).
- Net loss: kr6.09m (loss widened by 125% from 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Fluicell shares are down 64% from a week ago.
Risk Analysis
We should say that we've discovered 6 warning signs for Fluicell that you should be aware of before investing here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:FLUI
Fluicell
Operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology.
Medium-low with adequate balance sheet.
